S&P 500   3,382.09 (+1.45%)
DOW   27,951.64 (+0.96%)
QQQ   271.50 (+2.38%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.51 (+2.85%)
TSLA   1,527.24 (+11.12%)
GE   6.61 (-1.78%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.12 (-0.26%)
F   7.06 (-2.35%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   130.63 (+0.11%)
BAC   26.47 (-1.67%)
BA   174.25 (-3.26%)
S&P 500   3,382.09 (+1.45%)
DOW   27,951.64 (+0.96%)
QQQ   271.50 (+2.38%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.51 (+2.85%)
TSLA   1,527.24 (+11.12%)
GE   6.61 (-1.78%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.12 (-0.26%)
F   7.06 (-2.35%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   130.63 (+0.11%)
BAC   26.47 (-1.67%)
BA   174.25 (-3.26%)
S&P 500   3,382.09 (+1.45%)
DOW   27,951.64 (+0.96%)
QQQ   271.50 (+2.38%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.51 (+2.85%)
TSLA   1,527.24 (+11.12%)
GE   6.61 (-1.78%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.12 (-0.26%)
F   7.06 (-2.35%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   130.63 (+0.11%)
BAC   26.47 (-1.67%)
BA   174.25 (-3.26%)
S&P 500   3,382.09 (+1.45%)
DOW   27,951.64 (+0.96%)
QQQ   271.50 (+2.38%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.51 (+2.85%)
TSLA   1,527.24 (+11.12%)
GE   6.61 (-1.78%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.12 (-0.26%)
F   7.06 (-2.35%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   130.63 (+0.11%)
BAC   26.47 (-1.67%)
BA   174.25 (-3.26%)
Log in

NASDAQ:PODDInsulet Stock Price, Forecast & News

$204.10
+5.26 (+2.65 %)
(As of 08/12/2020 01:56 PM ET)
Add
Compare
Today's Range
$197.66
Now: $204.10
$205.27
50-Day Range
$186.97
MA: $200.85
$220.42
52-Week Range
$121.00
Now: $204.10
$233.99
Volume10,135 shs
Average Volume595,155 shs
Market Capitalization$12.88 billion
P/E Ratio728.95
Dividend YieldN/A
Beta0.89
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. It sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, and internationally. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Read More
Insulet logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$738.20 million
Cash Flow$0.60 per share
Book Value$1.23 per share

Profitability

Net Income$11.60 million

Miscellaneous

Employees1,350
Market Cap$12.88 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$204.10
+5.26 (+2.65 %)
(As of 08/12/2020 01:56 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Insulet (NASDAQ:PODD) Frequently Asked Questions

How has Insulet's stock been impacted by COVID-19 (Coronavirus)?

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has increased by 18.7% and is now trading at $204.27.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Insulet?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet
.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Insulet
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Thursday, August, 6th. The medical instruments supplier reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.23. The medical instruments supplier earned $226.30 million during the quarter, compared to analysts' expectations of $212.41 million. Insulet had a net margin of 2.20% and a return on equity of 24.43%. The business's revenue was up 27.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.02 earnings per share.
View Insulet's earnings history
.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $863.694-878.458 million, compared to the consensus revenue estimate of $849.76 million.

What price target have analysts set for PODD?

20 Wall Street analysts have issued 1 year price targets for Insulet's stock. Their forecasts range from $165.00 to $260.00. On average, they expect Insulet's stock price to reach $223.00 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for Insulet
.

Has Insulet been receiving favorable news coverage?

Headlines about PODD stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Insulet earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Insulet
.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Alibaba Group (BABA), Netflix (NFLX), salesforce.com (CRM), Tesla (TSLA), Roku (ROKU), Square (SQ), Trade Desk (TTD) and Walt Disney (DIS).

Who are Insulet's key executives?

Insulet's management team includes the following people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of institutional and retail investors. Top institutional investors include Mint Tower Capital Management B.V. (12.74%), William Blair Investment Management LLC (1.43%), Frontier Capital Management Co. LLC (1.29%), Victory Capital Management Inc. (0.66%), Sumitomo Mitsui Trust Holdings Inc. (0.49%) and KAMES CAPITAL plc (0.48%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet
.

Which major investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Russell Investments Group Ltd., Chartwell Investment Partners LLC, First Trust Advisors LP, GW&K Investment Management LLC, KAMES CAPITAL plc, Sumitomo Mitsui Trust Holdings Inc., and Amalgamated Bank. Company insiders that have sold Insulet company stock in the last year include Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet
.

Which major investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., SeaTown Holdings Pte. Ltd., Jag Capital Management LLC, Jennison Associates LLC, Frontier Capital Management Co. LLC, Granite Investment Partners LLC, Columbus Circle Investors, and State of Alaska Department of Revenue.
View insider buying and selling activity for Insulet
.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $204.27.

How big of a company is Insulet?

Insulet has a market capitalization of $12.89 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.